The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column reviews various issues related to the preparation, dispensing, and administration of cancer chemotherapy, both commercially available and investigational.
Get full access to this article
View all access options for this article.
References
1.
DeVitaV.T., MauchP.M., HarrisN.L.Hodgkin's disease. In: DeVitaV.T., HellmanS., RosenbergS.A., ed. Cancer: Principles and Practice of Oncology.5th ed.Philadelphia: Lippincott-Raven; 1997, 2242–83.
2.
National Comprehensive Cancer Network. NCCN practice guidelines for Hodgkin's disease.The Complete Library of NCCN Oncology Practice Guidelines [CD-ROM, version 2000].Rockledge, PA: National Comprehensive Cancer Network; 2000.
3.
CanellosG.P., AndersonJ.R., PropertK.J.Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med.1992; 327: 1478–84.
4.
BonadonnaG.Historical review of Hodgkin's disease. Br J Haematol.2000; 110: 504–11.
5.
DeVitaV.T., SerpickA.A., CarboneP.P.Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med.1970; 73: 881–95.
6.
BonadonnaG., ZucaliR., MonfardiniS.Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer.1975; 36: 252–9.
7.
LongoD.L., DuffeyP.L., DeVitaV.T.Treatment of advanced-stage Hodgkin's disease: Alternating noncrossre-sistant MOPP/CABS is not superior to MOPP. J Clin Oncol.1991; 9: 1409–20.
8.
NissenN.I., PajakT.F., GlidewellO.A comparative study of a BCNU containing 4-drug program versus MOPP versus 3-drug combinations in advanced Hodgkin's disease. Cancer.1979; 43: 31–40.
9.
BakemeierR.F., AndersonJ.R., CostelloW.BCVPP chemotherapy for advanced Hodgkin's disease: Evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Ann Intern Med.1984; 101: 447–56.
10.
HuguleyC.M., DurantJ.R., MooresR.R.A comparison of nitrogen mustard, vincristine, procarbazine, and prednisone (MOPP) vs. nitrogen mustard in advanced Hodgkin's disease. Cancer.1975; 36: 1227–40.
11.
SomersR., CardeP., Henry-AmarM.A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alternation of MOPP with ABVD: A European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierreet-Marie-Curie controlled clinical trial. J Clin Oncol.1994; 12: 279–87.
12.
HancockB.W.Randomised study of MOPP (mustine, oncovin, procarbazine, prednisone) against LOPP (leukeran substituted for mustine) in advanced Hodgkin's disease. British National Lymphoma Investigation. Radiother Oncol.1986; 7: 215–21.
13.
MooreM.R., JonesS.E., BullJ.M.MOPP chemotherapy for advanced Hodgkin's disease, prognostic factors in 81 patients. Cancer.1973; 32: 52–60.
14.
McCuneJ.S., LindleyC.Appropriateness of maximumdose guidelines for vincristine. Am J Health Syst Pharm.1997; 54: 1755–8.
15.
TrisselL.A., ZhangY., CohenM.R.The stability of diluted vincristine sulfate used as a deterrent to inadvertent intrathecal injection. Hosp Pharm.2001; 36: 740–5.
16.
HeskethP.J., KrisM.G., GrunbergS.M.Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol.1997; 15: 103–9.
17.
American Society of Health-System Pharmacists.ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health Syst Pharm.1999; 56: 729–64.
18.
National Comprehensive Cancer Network.NCCN antiemesis practice guidelines. The Complete Library of NCCN Oncology Practice Guidelines [CD-Rom, version 2000].Rockledge, PA: National Comprehensive Cancer Network; 2000.
19.
GrallaR.J., OsobaD., KrisM.G.Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines. J Clin Oncol.1999; 17: 2971–94.
OzerH., ArmitageJ.O., BennettC.L.2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. J Clin Oncol.2000; 18: 3558–85.
LymanG.H., KudererN., GreeneJ.The economics of febrile neutropenia: Implications for the use of colony-stimulating factors. Eur J Cancer.1998; 34: 1857–64.
24.
LymanG.H., BalducciL.Update of the economic analyses of the use of colony stimulating factors. Curr Opin Hematol.1999; 6: 145–51.
25.
LymanG.H.A novel approach to maintain planned dose chemotherapy on time: A decision-making tool to improve patient care. Eur J Cancer.2000; 36: S15–S21.
26.
DunlopD.J., EatockM.M., AndersonP.J.Randomized multicentre trial of filgrastim as an adjunct to combination chemotherapy for Hodgkin's disease. West of Scotland Lymphoma Group. Clin Oncol.1998; 10: 107–14.
27.
MullinS., BeckwithM.C., TylerL.S.Prevention and management of antineoplastic extravasation injury. Hosp Pharm.2000; 35: 57–74.
28.
KintzelP.E., DorrR.T.Anticancer drug renal toxicity and elimination: Dosing guidelines for altered renal function. Cancer Treat Rev.1995; 21: 33–64.
29.
KingP.D., PerryM.C.Hepatotoxicity of chemotherapeutic and oncologic agents. Gastroenterol Clin North Am.1995; 24: 969–89.
30.
HaimN., EpelbaumR., Ben-ShaharM.Full dose vin-cristine (without 2-mg dose limit) in the treatment of lymphomas. Cancer.1994; 73: 2515–9.
